The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Open accessAbstract
Purpose: We compared the efficacy of ofatumumab (O) versus rituximab (R) in combination with cisplatin, cytarabine, and dexamethasone (DHAP) salvage treatment, followed by autologous stem-cell transplantation (ASCT) in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Patients and Methods: Patients with CD20+ DLBCL age ≥ 18 years who had experienced their first relapse or who were refractory to first-line R-CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone)–like treatment were randomly assigned between three cycles of R-DHAP or O-DHAP. Either O 1,000 mg or R 375 mg/m 2 was administered for a total of four infusions (days 1 and 8 of cycle 1; day 1 of cycles 2 and 3 of DHAP). Patients who experienced a response after two cycles of treatment received the third cycle, followed by high-dose therapy and ASCT. Primary end point was progression-free survival (PFS), with failure to achieve a response after cycle 2 included as an event. Results: Between March 2010 and December 2013, 447 patients were randomly assigned. Median age was 57 years (range, 18 to 83 years); 17% were age ≥ 65 years; 63% had stage III and IV disease; 71% did not achieve complete response (CR) or experience response for < 1 year on first-line R-CHOP. Response rate for O-DHAP was 38% (CR, 15%) versus 42% (CR, 22%) for R-DHAP. ASCT on protocol was completed by 74 patients (33%) in the O arm and 83 patients (37%) in the R arm. PFS, event-free survival, and overall survival were not significantly different between O-DHAP versus R-DHAP: PFS at 2 years was 24% versus 26% (hazard ratio [HR], 1.12; 95% CI, 0.89 to 1.42; P = .33); event-free survival at 2 years was 16% versus 18% (HR, 1.10; P = .35); and overall survival at 2 years was 41% versus 38% (HR, 0.90; P = .38). Positron emission tomography negativity before ASCT was highly predictive for superior outcome. Conclusion: No difference in efficacy was found between O-DHAP and R-DHAP as salvage treatment of relapsed or refractory DLBCL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rituximab (monoclonal anti-CD20 antibody): mechanisms of action and resistance
Smith, M. R. (2003) · Oncogene · doi:10.1038/sj.onc.1206939 · Cited by 835
Research works printed but not linked: 24
- 10.1056/NEJMoa011795 · DOI · Paper page
- 10.1200/JCO.2005.09.131 · DOI · Paper page
- 10.1016/S1470-2045(06)70664-7 · DOI · Paper page
- 10.1016/S1470-2045(08)70002-0 · DOI · Paper page
- 10.1200/JCO.2005.05.1003 · DOI · Paper page
- 10.1200/JCO.2005.09.137 · DOI · Paper page
- 10.1056/NEJM199512073332305 · DOI · Paper page
- 10.1182/blood-2007-08-108415 · doi:10.1182/blood-2007-08-108415
- 10.3324/haematol.13440 · DOI · Paper page
- 10.1200/JCO.2010.28.1618 · DOI · Paper page
- 10.4049/jimmunol.177.1.362 · DOI · Paper page
- 10.1111/j.1365-2141.2011.08966.x · DOI
- 10.1182/blood-2007-09-111781 · DOI · Paper page
- 10.1182/blood-2007-10-117671 · DOI · Paper page
- 10.1182/blood-2012-12-472027 · DOI
- 10.1182/blood-2002-12-3837 · DOI · Paper page
- 10.1200/JCO.2006.09.2403 · DOI · Paper page
- 10.1200/JCO.2006.08.2305 · DOI · Paper page
- 10.1200/JCO.1998.16.10.3264 · doi:10.1200/jco.1998.16.10.3264
- 10.1182/blood-2014-10-606939 · doi:10.1182/blood-2014-10-606939
- 10.1158/1078-0432.CCR-09-1624 · DOI · Paper page
- 10.1182/blood-2008-08-175208 · DOI · Paper page
- 10.1200/JCO.2013.53.9593 · DOI · Paper page
- 10.1038/nrclinonc.2014.137 · DOI
Cited by
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
Locke, F. L., Miklos, D. B., Jacobson, C. A., Perales, M.-A., Kersten, M.-J., Oluwole, O. O., Ghobadi, A., Rapoport, A. P., McGuirk, J., Pagel, J. M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116133 · Cited by 1,607
Kamdar, M., Solomon, S. R., Arnason, J., Johnston, P. B., Glass, B., Bachanova, V., Ibrahimi, S., Mielke, S., Mutsaers, P., Hernandez-Ilizaliturri, F., et al. (2022) · The Lancet · doi:10.1016/s0140-6736(22)00662-6 · Cited by 799
Glofitamab for Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Dickinson, M. J., Carlo-Stella, C., Morschhauser, F., Bachy, E., Corradini, P., Iacoboni, G., Khan, C., Wróbel, T., Offner, F., Trněný, M., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206913 · Cited by 761
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
Bishop, M. R., Dickinson, M., Purtill, D., Barba, P., Santoro, A., Hamad, N., Kato, K., Sureda, A., Greil, R., Thieblemont, C., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2116596 · Cited by 538
Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma
Westin, J. R., Oluwole, O. O., Kersten, M. J., Miklos, D. B., Perales, M.-A., Ghobadi, A., Rapoport, A. P., Sureda, A., Jacobson, C. A., Farooq, U., et al. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301665 · Cited by 455
Metadata
- Authors
- van Imhoff, G. W., McMillan, A., Matasar, M. J., Radford, J., Ardeshna, K. M., Kuliczkowski, K., Kim, W., Hong, X., Goerloev, J. S., Davies, A., Barrigón, M. D. C., Ogura, M., Leppä, S., Fennessy, M., Liao, Q., van der Holt, B., Lisby, S., & Hagenbeek, A.
- Venue
- Journal of Clinical Oncology
- Published
- 2017-02-10
- Volume
- 35
- Issue
- 5
- Pages
- 544-551
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2565561569
- Cited by
- 235
- References
- 1
- FWCI
- 15.21
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. https://app.cochat.ai/papers/10.1200/jco.2016.69.0198
- The paper
- van Imhoff, G. W., McMillan, A., Matasar, M. J., Radford, J., Ardeshna, K. M., Kuliczkowski, K., Kim, W., Hong, X., Goerloev, J. S., Davies, A., Barrigón, M. D. C., Ogura, M., Leppä, S., Fennessy, M., Liao, Q., van der Holt, B., Lisby, S., & Hagenbeek, A. (2017). Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2016.69.0198
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.